Azitra, Inc.’s ATR-04 Takes Aim at EGFRi-induced Dermal Toxicity
ATR-04 may help address epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 people in the US, according to preclinical data presented on at the Society of Investigative Dermatology (SID) 2024 Annual Meeting in Dallas, TX. ATR-04 is a live biotherapeutic product candidate consisting of an S. epidermidis strain that was isolated from a […]